Evaluation of safety and efficacy of K-877 in patients with statin-controlled LDL-C but abnormal lipid levels
Latest Information Update: 16 Mar 2022
Price :
$35 *
At a glance
- Drugs Pemafibrate (Primary)
- Indications Dyslipidaemias; Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical
- 03 Mar 2022 Primary endpoint (Percentage change in non high density lipoprotein cholesterol level from baseline to Week 12) has not been met as per results published in the Diabetes Care
- 03 Mar 2022 Primary endpoint (Percentage change in triglyceride levels from baseline to Week 12) has been met as per results published in the Diabetes Care
- 03 Mar 2022 Results published in the Diabetes Care